FrancophonIA/ELRC3.0 huggingface dataset:
English: Studies have been carried out to prove that Acticam is ‘bioequivalent' to the reference veterinary medicine: this means that Acticam is equivalent to Metacam 1.5 mg/ml suspension in the way it is absorbed and used by the body.
Maltese: Twettqu studji sabiex juru li Acticam huwa ‘bijoekwivalenti' għall-mediċina veterinarja ta' referenza: dan ifisser li Acticam huwa ekwivalenti għal Metacam 1.5 mg/ml ta' sospensjoni fil-mod ta' kif jiġi assorbit u użat millġisem.
English: Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.
Maltese: Acticam huwa effikaċi fis-serħan tal-infjammazzjoni u uġigħ f'mard muskoluskeletriku kemm akut kif ukoll kroniku u biex inaqqas l-uġigħ wara operazzjoni ortopedika u tat-tessut artab fil-klieb u fittnaqqis tal-uġigħ ta' wara operazzjoni fejn jitneħħew l-ovarji u l-utru u ta' wara operazzjoni minuri tat-tessut artab fil-qtates.
English: Acticam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Maltese: Acticam fih meloxicam, li jappartjeni għall-klassi ta' mediċini msejħin mediċini antinfjammatorji mhux sterojdali (NSAIDs). Meloxicam jaġixxi billi jinibixxi s-sintesi tal-prostaglandini.
English: What benefit has Acticam shown during the studies?
Maltese: Liema benefiċċju wera Acticam waqt l-istudji mwettqa?
English: How does Acticam work?
Maltese: Għal xiex jintuża Acticam?
English: People with known hypersensitivity (allergic) to meloxicam should avoid contact with the product.
Maltese: Persuni li huma ipersensittivi (allerġiċi) għal meloxicam għandhom jevitaw kuntatt mal-prodott.
English: This summary was last updated in January 2012.
Maltese: Jannar 2012.
English: A study looked at how Acticam was absorbed and its effects in the body, in comparison with Metacam oral suspension 1.5mg/ml.
Maltese: Sar studju li ħares lejn kif Acticam ġie assorbit u l-effetti tiegħu fil-ġisem, meta mqabbla ma' 1.5mg/ml ta' sospensjoni orali Metacam.
English: An oral follow-up therapy using meloxicam or other NSAIDs should not be used in cats, as no safe dosage for repeated oral administration has been established.
Maltese: Terapija orali ta' segwitu bl-użu ta' meloxicam jew NSAIDs oħrajn mgħandux jingħata fil-qtates, minħabba li l-ebda dożaġġ sikur għadu ma ġie stabbilit għall-amministrazzjoni orali ripetuta.
English: Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Maltese: Tnaqqis tal-uġigħ ta' wara operazzjoni fejn jitneħħew l-ovarji u l-utru u operazzjoni minuri tat-tessut artab.
English: These side effects occur usually within the first week of treatment and are generally temporary.
Maltese: Dawn l-effetti sekondarji jidhru normalment matul l-ewwel ġimgħa tat-trattament u huma ġeneralment temporanji.
English: The full EPAR for CellCept can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: CellCept mycophenolate mofetil
Maltese: CellCept mikofonelat mofetil
English: It is available as capsules (250 mg), tablets (500 mg), a powder to be made up into an oral suspension (1 g/5 ml) and a powder to be made up into a solution for infusion (drip) into a vein (500 mg).
Maltese: Jiġi bħala kapsuli (250 mg), pilloli (500 mg), trab li jinħall f'sospensjoni orali (1 g/5 ml) u trab li jinħall f'soluzzjoni għall-infużjoni (dripp) fil-vina (500 mg).
English: The most common side effects with CellCept used in combination with ciclosporin and corticosteroids (seen in more than 1 patient in 10) are sepsis (blood infection), gastrointestinal candidiasis (a fungal infection of the stomach or gut), urinary tract infection (infection of the structures that carry urine), herpes simplex (a viral infection that causes cold sores), herpes zoster (a viral infection that causes chickenpox and shingles), leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), vomiting, abdominal (tummy) pain, diarrhoea and nausea (feeling sick).
Maltese: L-effetti sekondarji l-aktar komuni b'CellCept użat f'kombinazzjoni ma' ċiklosporina u korticosterojdi (li dehru f'iktar minn pazjent wieħed minn kull 10) huma s-sepsis (infezzjoni fiddemm), il-kandidjażi gastrointestinali (infezzjoni fungali tal-istonku jew tal-musrana), infezzjoni fil-pajp li minnu tgħaddi l-awrina, herpes simplex (infezzjoni virali li tikkawża selħiet fix-xufftejn), herpes zoster (infezzjoni virali li tikkawża l-ġidri riħ u l-ħruq ta' Sant'Antnin), il-lewkopenja (tnaqqis fl-għadd ta' ċelloli tad-demm bojod), tromboċitopenija (tnaqqis fil-livelli tal-pjastrini fid-demm), rimettar, uġigħ ta' żaqq, dijarrea u nawżja.
English: This summary was last updated in 11-2015.
Maltese: Dan is-sommarju ġie aġġornat f'11-2015.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom between two and 18 years, the dose of CellCept is calculated depending on height and weight and should be given by mouth.
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: CellCept capsules and tablets have been studied in three studies involving a total of 1,493 adults following kidney transplant, in one study involving 650 adults following heart transplant and in one study involving 565 adults following liver transplant.
Maltese: Il-kapsuli u l-pilloli ta' CellCept ġew studjati fi tliet studji li fihom ħadu sehem 1,493 adult wara trapjant tal-kliewi, 650 adult wara trapjant tal-qalb fi studju wieħed, u 565 adult wara trapjant tal-fwied fi studju ieħor.
English: Other information about CellCept
Maltese: Informazzjoni oħra dwar CellCept
English: This is a summary of the European public assessment report (EPAR) for CellCept.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal CellCept.
English: The active substance in CellCept, mycophenolate mofetil, is an immunosuppressive medicine.
Maltese: Is-sustanza attiva f'CellCept, il-mikofenolat mofetil hija mediċina immunosuppressiva.
English: CellCept is a medicine containing the active substance mycophenolate mofetil.
Maltese: CellCept huwa mediċina li fiha s-sustanza attiva mikofenolat mofetil.
English: What is CellCept?
Maltese: X'inhu CellCept?
English: It is used with ciclosporin and corticosteroids (other medicines used to prevent organ rejection).
Maltese: Jintuża flimkien maċ-ċiklosporina u l-kortikosterojdi (mediċini oħra użati biex jipprevjenu li l-organi ma jiġux aċċettati).
English: Following liver transplant, 38% of the adult patients taking CellCept had rejected their new liver after six months, compared with 48% of those taking azathioprine, but the proportion of patients who had lost their new liver after a year was similar in the two groups, at around 4%.
Maltese: Wara t-trapjant tal-fwied, 38% tal-pazjenti li kienu qed jieħdu CellCept ma aċċettawx il-fwied il-ġdid wara sitt xhur, meta mqabbla ma' 48% ta' dawk li kienu qed jieħdu l-ażatijoprina, iżda l-proporzjon ta' pazjenti li kienu tilfu l-fwied il-ġdid wara sena kien simili fiż-żewġ gruppi, madwar 4%.
English: It can also be given as an infusion lasting two hours starting within 24 hours after the transplant, for up to 14 days.
Maltese: Jista' jingħata wkoll bħala infużjoni ta' sagħtejn li tibda minn 24 siegħa sa 14-il jum wara li jkun sar it-trapjant.
English: In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase'.
Maltese: Fil-ġisem, tinbidel f'aċidu mikofenoliku, li jimblokka enżima magħruf bħala inosina monofosfat deidrogenażi.
English: For kidney transplants, the recommended dose in adults is 1 g twice a day by mouth (capsules, tablets or oral suspension) starting within 72 hours after the transplant.
Maltese: Għat-trapjanti tal-kliewi, id-doża rakkomandata fl-adulti hija 1 g darbtejn kuljum oralment (kapsuli, pilloli jew sospensjoni orali) u tibda minn 72 siegħa wara t-trapjant.
English: The European Commission granted a marketing authorisation valid throughout the European Union for CellCept on 14 February 1996.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal CellCept fl-14 ta' Frar 1996.
English: For the full list of side effects reported with CellCept, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrappurtati b'CellCept, ara l-fuljett ta' tagħrif.
English: The company that markets CellCept will provide educational materials for patients and healthcare professionals explaining the risk of harm to a developing baby and the precautions and measures to be taken to avoid pregnancy during treatment.
Maltese: Il-kumpanija li tikkummerċjalizza CellCept ser tipprovdi materjali edukattivi għall-pazjenti u għallprofessjonisti fil-kura tas-saħħa li jispjegaw ir-riskju ta' ħsara għal tarbija li tkun qed tiżviluppa u lprekawzjonijiet u l-miżuri li jridu jittieħdu biex tiġi evitata tqala waqt il-kura.
English: For more information, see the summary of product characteristics (also part of the EPAR).
Maltese: Għal aktar informazzjoni, ara ssommarju tal-karatteristiċi tal-prodott (parti wkoll mill-EPAR).
English: Why has CellCept been approved?
Maltese: Għaliex ġie approvat CellCept?
English: The most serious risk associated with CellCept is the possible development of cancer, particularly lymphoma and skin cancer.
Maltese: L-iktar riskju serju assoċjat ma' CellCept huwa l-possibilità tal-iżvilupp tal-kankru, partikolarment linfoma u fil-ġilda.
English: What measures are being taken to ensure the safe and effective use of CellCept?
Maltese: X'miżuri qed jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' CellCept?
English: For liver transplants in adults, CellCept should be given as a 1-g infusion twice a day for the first four days after the transplant, before the patient is switched to 1.5 g twice a day by mouth as soon as it can be tolerated.
Maltese: Għat-trapjanti tal-qalb, id-doża rakkomandata għall-adulti hija 1.5 g oralment darbtejn kuljum, li għandha tibda minn ħamest ijiem wara t-trapjant.
English: Further studies showed that the solution for infusion and the oral suspension produced similar levels of the active substance in the blood as the capsules.
Maltese: Studji oħra wrew li s-soluzzjoni għall-infużjoni u s-sospensjoni orali wasslu għal livelli simili tassustanza attiva fid-demm daqs dik fil-kapsuli.
English: In children undergoing kidney transplants, the rejection rates were similar to those seen in adults taking CellCept and lower than those seen in other studies of children who did not receive CellCept.
Maltese: Għaldaqstant, CellCept ma għandux jintuża waqt it-tqala sakemm m'hemmx alternattiva xierqa biex tipprevjeni li l-organi trapjantati ma jiġux aċċetti.
English: What is the risk associated with CellCept?
Maltese: Għal xiex jintuża CellCept?
English: How has CellCept been studied?
Maltese: Kif ġie studjat CellCept?
English: CellCept was compared with azathioprine (another anti-rejection medicine) in all studies except for one of the kidney transplant studies, in which it was compared with placebo (a dummy treatment).
Maltese: CellCept tqabbel mal-ażatioprina (mediċina oħra li tgħin biex l-organi trapjantati jiġu aċċettati) fl-istudji kollha ħlief f'wieħed mill-istudji tal-kura tal-kliewi, li fih tqabbel ma' plaċebo (kura finta).
English: CellCept was as effective as azathioprine and more effective than placebo in preventing the rejection of transplanted kidneys after six months.
Maltese: CellCept kien effettiv daqs l-ażatijoprina u iktar effettiv mill-plaċebo fil-prevenzjoni li kliewi trapjantati ma jiġux aċċettati wara sitt xhur.
English: In the heart transplant study, around 38% of adult patients taking CellCept and those taking azathioprine experienced rejection after six months.
Maltese: Fl-istudju tat-trapjanti tal-qalb, madwar 38% tal-pazjenti li ngħataw CellCept u dawk li kienu qed jieħdu l-ażatijoprina ma aċċettawx l-organu wara sitt xhur.
English: The CHMP decided that CellCept's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' CellCept huma akbar mir-riskji tiegħu u għaldaqstant irrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: EU (MA) Number
Maltese: Numru tal-UE (MA) Isem (ivvintat) Qawwa Għamla Farmaċewtika
English: Suspension: 1.5 ml Emulsion: 4.5 ml
Maltese: suspensjoni : 1.5 ml emulsjoni : 4.5 ml
English: 3.8 micrograms HA**
Maltese: 3.8 mikrogrammi**
English: 3.8 µg HA
Maltese: 3.8 μg HA
English: 10 vials (suspension)
Maltese: 10 kunjett (suspensjoni)
English: AF03 adjuvant composed of squalene (12.4 milligrams), sorbitan oleate (1.9 milligrams), polyoxyethylene cetostearyl ether (2.4 milligrams) and mannitol (2.3 milligrams)
Maltese: AF03 stimulant magħmul minn squalene (12,4milligrammi), sorbitan oleate (1,9 milligrammi), polyoxyethylene cetostearyl ether (2,4 milligrammi) u mannitol (2,3 milligrammi)
English: 10 vials (emulsion)
Maltese: 10 kunjett (emulsjoni)
English: Split Influenza virus, inactivated, containing antigen* equivalent to: A/California/7/2009 (H1N1)-like strain (NYMC X-179A)
Maltese: Virus maqsum, mhux attivat ta' l-influwenza li jkun fih antiġen* ekwivalenti għal: Razza (X-179A) tixbaħ lil A/California/2009 (H1N1)
English: Suspension and emulsion for emulsion for injection
Maltese: Suspensjoni u emulsjoni għal emulsjoni għall injezzjoni
English: * propagated in eggs ** haemagglutinin
Maltese: * imnissla fil-bajd ** emagglutinina
English: Suspension (H1N1): vial (glass);
Maltese: Jingħata filmuskolu suspensjoni (H1N1): kunjett (ħġieġ)
English: After mixing, 1 dose (0.5 ml) contains:
Maltese: Wara li titħallat, doża 1 (0.5 ml) ikun fiha:
English: Emulsion (adjuvant): vial (glass)
Maltese: emulsjoni (suppliment): kunjett (ħġieġ)
English: EMA/121019/2014 EMEA/H/C/003890
Maltese: EMEA/H/C/003890
English: This summary was last updated in 04-2014.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi 04-2014.
English: BiResp Spiromax is a ‘hybrid medicine'.
Maltese: BiResp Spiromax huwa ‘mediċina ibrida'.
English: The full EPAR and risk management plan summary for BiResp Spiromax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ u s-sommarju tal-pjan tal-ġestjoni tar-riskju għal BiResp Spiromax jinstabu fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Formoterol is a long-acting beta-2 agonist.
Maltese: Formoterol huwa agonist beta-2 li jaħdem fit-tul.
English: The reference medicine for BiResp Spiromax is Symbicort Turbohaler.
Maltese: Il-mediċina ta' referenza għal BiResp Spiromax hija Symbicort Turbohaler.
English: The higher strength, BiResp Spiromax 320/9 microgram (320 micrograms of budesonide and 9 micrograms of formoterol), can only be used for the regular treatment of asthma and for the treatment of COPD.
Maltese: Hija tista' tintuża wkoll għall-kura ta' COPD. L-ogħla qawwa, BiResp Spiromax 320/9 mikrogrammi (320 mikrogramma ta' budesonide u 9 mikrogrammi ta' formoterol), tista' tintuża biss għall-kura regolari tal-ażżma u għall-kura tas-COPD.
English: The European Commission granted a marketing authorisation valid throughout the European Union for BiResp Spiromax on 28 April 2014.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq fl-Unjoni Ewropea kollha għal BiResp Spiromax fit-28 ta' April 2014.
English: This means that it is similar to a ‘reference medicine' containing the same active substances, but BiResp Spiromax is given using a different inhaler.
Maltese: Dan ifisser li huwa simili għal 'mediċina ta' referenza' li fiha listess sustanzi attivi, iżda BiResp Spiromax jingħata bl-użu ta' inalatur differenti.
English: A risk management plan has been developed to ensure that BiResp Spiromax is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li BiResp Spiromax jintuża bl-aktar mod sigur possibbli.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that BiResp Spiromax 160/4.5 microgram and 320/9 microgram have been shown to have comparable quality and to be bioequivalent to the corresponding strengths of Symbicort Turbohaler.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija kkonkluda li BiResp Spiromax 160/4.5 mikrogramma u 320/9 mikrogramma wera li għandu kwalità komparabbli u huwa bijoekwivalenti għall-qawwiet korrespondenti ta' Symbicort Turbohaler.
English: Other information about BiResp Spiromax
Maltese: Informazzjoni oħra dwar BiResp Spiromax
English: This is a summary of the European public assessment report (EPAR) for BiResp Spiromax.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal BiResp Spiromax.
English: Budesonide belongs to a group of anti-inflammatory medicines known as corticosteroids.
Maltese: Budesonide jappartjeni għal grupp ta' mediċini anti-infjammatorji magħrufin bħala kortikosterojdi.
English: BiResp Spiromax is a medicine that contains the active substances budesonide and formoterol.
Maltese: BiResp Spiromax huwa mediċina li fiha s-sustanzi attivi budesonide u formoterol.
English: BiResp Spiromax is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare-ups) of the disease in the past despite regular treatment.
Maltese: BiResp Spiromax jintuża wkoll biex itaffi s-sintomi tal-marda pulmonari ostruttiva kronika severa (COPD- chronic obstructive pulmonary disease) fl-adulti li kellhom aggravamenti (feġġiet) tal-marda fil-passat minkejja kura regolari.
English: It is available as an inhalation powder in a portable inhaler device, and each inhalation provides a fixed dose of the medicine.
Maltese: Tiġi bħala trab għall-inalazzjoni f'apparat inalatur portabbli, u kull inalazzjoni tipprovdi doża fissa tal-mediċina.
English: 160/4.5 microgram (160 micrograms of budesonide and 4.5 micrograms of formoterol) can be used for the regular treatment of asthma and when needed as a reliever.
Maltese: (160 mikrogramma ta' budesonide u 4.5 mikrogramma ta' formoterol) jista' jintuża għall-kura regolari tal-ażżma u meta meħtieġa biex ittaffi.
English: As asthma reliever therapy, patients can take 1 or 2 additional inhalations of BiResp Spiromax 160/4.5 microgram only to relieve their symptoms.
Maltese: Bħala terapija għat-taffija tal-ażżma, il-pazjenti jistgħu jieħdu 1 jew 2 inalazzjonijiet addizzjonali ta' BiResp Spiromax 160/4.5 mikrogramma biss biex itaffu s-sintomi tagħhom.
English: Because BiResp Spiromax is a hybrid medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li BiResp Spiromax huwa mediċina ibrida u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Studies in patients have been limited to tests to determine that BiResp Spiromax is bioequivalent to the reference medicine, Symbicort Turbohaler.
Maltese: L-istudji f'pazjenti ġew limitati għal testijiet biex jiddeterminaw li BiResp Spiromax huwa bijoekwivalenti għall-mediċina ta' referenza, Symbicort Turbohaler.
English: Why is BiResp Spiromax approved?
Maltese: Għaliex ġie approvat BiResp Spiromax?
English: It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors in various types of immune cell.
Maltese: Huwa jaħdem b'mod simili għal ormoni kortikosterojdi li jseħħu b'mod naturali, billi jnaqqas l-attività tas-sistema immunitarja billi jintrabat ma' riċetturi f'diversi tipi ta' ċelloli immunitarji.
English: BiResp Spiromax
Maltese: Kif jintuża BiResp Spiromax?
English: It can be used in patients whose disease is not adequately controlled by treatment with other asthma medicines called corticosteroids and ‘short-acting beta-2 agonists' taken by inhalation, or in patients whose disease is adequately controlled by treatment with corticosteroids and ‘long-acting beta-2 agonists' taken by inhalation.
Maltese: Jista' jintuża f'pazjenti li l-marda tagħhom ma tkunx ikkontrollata b'mod adegwat permezz ta' kura b'mediċini oħrajn għall-ażżma li jissejħu kortikosterojdi u ‘agonisti tal-beta-2 li jaħdmu għal żmien qasir' li jittieħdu man-nifs, jew f'pazjenti li l-marda tagħhom hija kkontrollata b'mod adegwat permezz ta' kura bil-kortikosterojdi u ‘agonisti tal-beta-2 li jaħdmu fit-tul' li jittieħdu man-nifs.
English: How has BiResp Spiromax been studied?
Maltese: Kif ġie studjat BiResp Spiromax?
English: What are the benefits and risks of BiResp Spiromax?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' BiResp Spiromax?
English: The two active substances in BiResp Spiromax are well known and are present in several medicines used to treat asthma and COPD, either alone or in combination with other medicines.
Maltese: Iż-żewġ sustanzi attivi f'BiResp Spiromax huma magħrufa sew u huma preżenti f'diversi mediċini użati biex jikkuraw l-ażżma u COPD, jew waħedhom jew flimkien ma' mediċini oħrajn.
English: How does BiResp Spiromax work?
Maltese: Kif jaħdem BiResp Spiromax?
English: The company initially also applied for a lower strength of BiResp Spiromax, however bioequivalence to the reference product was not demonstrated and the application for this strength was withdrawn.
Maltese: Il-kumpanija inizjalment applikat ukoll għal doża aktar baxxa ta' BiResp Spiromax, madankollu ma ntwerietx il-bijoekwivalenza mal-prodott ta' referenza u l-applikazzjoni għal din il-qawwa ġiet irtirata.
English: OPA/aluminium/PVC-aluminium blisters.
Maltese: OPA/aluminju/PVC-aluminju.
English: Colloidal anhydrous silica
Maltese: Colloidal anhydrous silica Magnesium stearate
English: Other medicines and SIFROL
Maltese: Mediċini oħra u SIFROL
English: You should avoid taking SIFROL together with antipsychotic medicines.
Maltese: Għandek tevita li tieħu SIFROL flimkien ma' mediċini antipsikotiċi.
English: SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets
Maltese: SIFROL 0.088 mg pilloli SIFROL 0.18 mg pilloli SIFROL 0.35 mg pilloli SIFROL 0.7 mg pilloli
English: Date of latest renewal: 14 October 2007
Maltese: Data tal-aħħar tiġdid: 14 ta' Ottubru, 2007
English: SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets Pramipexole
Maltese: SIFROL 0.088 mg pilloli SIFROL 0.18 mg pilloli SIFROL 0.35 mg pilloli SIFROL 0.7 mg pilloli Pramipexole
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 October 1997
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 14 ta' Ottubru, 1997
English: Table 1: Parkinson's disease Body System Very common
Maltese: Tabella 1: Marda ta' Parkinson Sistema tal-Ġisem Komuni ħafna
English: SIFROL 0.35 mg tablets EU/1/97/050/011-012
Maltese: SIFROL 0.35 mg pilloli EU/1/97/050/011-012
English: SIFROL 0.7 mg tablets EU/1/97/050/005-006
Maltese: SIFROL 0.7 mg pilloli EU/1/97/050/005-006
English: SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets
Maltese: SIFROL 0.26 mg pilloli li jerħu l-mediċina bil-mod SIFROL 0.52 mg pilloli li jerħu l-mediċina bil-mod SIFROL 1.05 mg pilloli li jerħu l-mediċina bil-mod SIFROL 1.57 mg pilloli li jerħu l-mediċina bil-mod SIFROL 2.1 mg pilloli li jerħu l-mediċina bil-mod SIFROL 2.62 mg pilloli li jerħu l-mediċina bil-mod SIFROL 3.15 mg pilloli li jerħu l-mediċina bil-mod
English: SIFROL 0.088 mg tablets
Maltese: SIFROL 0.088 mg pilloli
English: SIFROL 0.35 mg tablets
Maltese: SIFROL 0.35 mg pilloli